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Abstract  
Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative disorder 
characterized by both motor and non-motor symptoms. The motor symptoms 
include bradykinesia and resting tremor while the non-motor symptoms associate 
with sleeping disorders and olfactory dysfunctions. Besides that, patients may 
experience hyposmia prior being diagnosed with PD. Thus, the present project’s 
objective is to confirm a new dopaminergic pathway, which contributes to 
hyposmia link in pre-exposed PD patients. In order to validate the nigro-olfactory 
pathway, the MitoPark model was set up in the combination of several techniques 
including cryosectioning, mounting, and fluorescent microscopy. After collecting 
data, there were significant fluorescent of FG tracers emitted at Striatum. In order 
to validate the hypothesis, more fluorescent data need collecting specifically for 
Dil and CTB at the olfactory bulb.   
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Introduction  
 According to National Institute of Environmental Health Sciences, 
neurodegenerative diseases affect millions of people worldwide. Alzheimer’s 
disease and Parkinson’s disease are the most common types, with more than five 
million Americans living with Alzheimer’s, and at least 500,000 Americans living 
with Parkinson’s (Hollander & Lawler, 2019). Thus, understanding the 
pathogenesis, which underlies these chronic diseases, is essential to identify and 
explore new cures or treatments. In particular, Parkinson’s disease (PD) is a 
chronic pathology characterized by massive degeneration of dopaminergic neurons 
in the substania nigra, the loss of striatal dopaminergic fibers and a dramatic 
reduction of the striatal dopamine levels (Schober, 2004). 
 Many PD-diagnosed patients may experience both motor and non-motor 
symptoms, which were associated with the loss of striatal dopaminergic neurons. 
In PD, the motor symptoms include resting tremor, stiffness, slow walking, 
bradykinesia, and muscular rigidity while the non-motor pathophysiological 
changes associated with sleeping disorders, depression, olfactory dysfunction, and 
cognitive changes (DeMaagd & Philip, 2015).  
 In order to study PD and generate symptom-like on rodent model, there 
were several toxins utilized in the project. Several studies from Dr. Schober 
showed that exposing to dopamine (DA)-toxic compounds/chemicals via olfactory 
bulb such as 6-hydroxyl-dopamine (6-OHDA) and 1-methyl-4-phenyl-1, 2,3,6-
tetrahydropyridine (MPTP) was able to destroy catecholaminergic neurons 
(Schober, 2004) in PD model. According to Dr. Schober, 6-ODHA is an analogue 
of neurotransmitter dopamine, which induces the efficient and long lasting 
noradrenaline depletion in central nervous system to the heart. The accumulation 
of cystolic 6-OHDA initiates apoptosis via mitochondrial pathway. However, his 
model does not mimic all pathological and clinical features of Parkinsonism. It 
induces the dopaminergic neuron death but does not show the formation of Lewy 
bodies. Thus, it does not affect the anterior olfactory structures.  
 In addition, MPTP is an analogue of narcotic meperidine, which is lipid 
soluble and able to cross blood-brain barrier. MPTP is metabolized to MPDP via 
Monoamine oxidase B, which in turn accumulates as MPP+ as the final product. 
MPP+ uptake depends on active carriers such as VMAT and MPP since they 
transport vesicle-containing DA inside the cytoplasm. MPTP fails to show the 
formation of Lewy bodies in patients and monkey model. Summarizing Dr. 
Schober’s studies, there are two essential take-home messages. First, the presence 
of Lewis bodies at cellular level indicates the progression of PD. Second, MPP+ 
and 6-ODHA are two common toxins used in rodent model to initiate the 
apoptosis of dopaminergic neurons (Schober, 2004).   
 According to Dr. Alexander from Emory University School of Medicine, 
the neurons in substantia nigra are selectively vulnerable to the motor deficits in 
PD. They produce the neurotransmitter dopamine, which are responsible to relay 
messages that plan and control body movement. Progression of motor dysfunction 
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in PD is correlated with reductions of nigrostriatal dopamine terminals within the 
same striatal territories. Besides that, a complex chain of decisions involving inter-
connected ganglia controls the body movement. Information comes to a central 
area of the brain called striatum, which works with the substantia nigra to send 
impulses back and forth from the spinal cord to the brain (Alexander, 2004). 
Therefore, in PD patients, there is a significant decrease in the concentration of 
dopamine neural modulators from substantia nigra to striatum. This is known as a 
classic pathway observed in PD patients.  
 On a different study performed by Dr. Doty of University of Pennsylvania 
School of Medicine, the xenobiotics (prions, notably viruses) are able to enter the 
brain via the olfactory mucosa. The loss of smell occurs during preclinical phase 
of PD. 90% patients with early stage PD exhibit olfactory dysfunction via 
psychological and electrophysiological test (Doty, 2008). The neuropathy begins 
with Lewy bodies localized within the olfactory bulb, anterior olfactory nucleus, 
and dorsal motor nucleus of the vagus nerve and then advances through regions of 
medulla oblongata, mid brain, and basal forebrain. The finding confirmed the 
presence of Lewis bodies in olfactory bulb and anterior olfactory nucleus (Doty, 
2008). This suggested a different dopaminergic pathway, which starts from 
substantia nigra to olfactory bulb. If nigral neurons project tracts to the olfactory 
bulb in an addition to the striatum, then this pathway may provide a direct link 
between hyposmia and Parkinson’s disease.  
 In order to support the existence of new finding dopaminergic pathway, Dr. 
Bohnen from University of Michigan School of Medicine and his laboratory 
performed University of Pennsylvania Smell Identification Test (UPSIT) on 29 
subjects. The result showed that the correlation coefficients between total UPSIT 
scores and regional brain dopamine transporter binding potentials were highest for 
the hippocampus and lowest for dorsal striatum. Under selective hyposmia 
condition, the study suggested that, besides striatum, neurotransmitter dopamine 
might innervate other brain regions including hippocampus, which is in charged of 
olfactory cognitive and memory processing (Bohnen, Gedela, Herath, Constantine, 
& Moore, 2008).  
 In addition, olfactory system and olfactory signal transduction play crucial 
roles in hyposmia condition. The olfactory system detects airborne agents in the 
human respiratory system, which dissolve in the mucus that covering the surface 
of olfactory epithelium in the nasal cavity. In addition, olfactory epithelium 
contains around 6 million of bipolar receptor cells (cell bodies and dendrites) that 
contain odorant receptors. Together with taste sense, the sense of the smell is 
critical for food selection and has a strong affective component in the sexual and 
other behaviors. Moreover, olfactory bulb contains mitral cells that receive 
information from sensory neurons and in turn send projections to central 
pathways. It also contains other types of neurons and performs the first stage of 
information processing (Doty, 2009). 
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 According to Drs. Ronnett and Moon from Johns Hopkins Institute for 
Basic Biomedical Sciences, olfactory signal transduction is an interface of the 
environment and nervous system. The membranes of olfactory cilia contain 
odorant and G-protein coupled receptors. When odorants bound, the receptors are 
activated by adenylyl cyclase, which catalyzes formation of cyclic AMP (second 
messenger). Increased levels of cAMP open cAMP-gated Na+ channels, which 
depolarize cell receptor and generate an action potential leading to releasing 
glutamate neurotransmitter. Neurotransmitters then activate mitral cells in the 
olfactory bulb. Therefore, olfactory bulb plays vital role in olfactory signal 
transduction (Ronnett & Moon, 2002). 
 Hyposmia is a condition where the patients may loss partial of smell 
sensation. In a study published in January of 2004, Dr. Uylings showed that the 
total number of tyrosine hydroxylase-immunoreactive neurons in the olfactory 
bulb was twice as high in Parkinson patients compared to age and gender-matched 
controls. Because dopamine was known to inhibit olfactory transmission in the 
olfactory glomeruli, his team suggested that the increase of dopaminergic neurons 
in the olfactory bulb was responsible for the hyposmia in Parkinson patients 
(Huisman, Uylings, & Hoogland, 2004). He also found that increasing dopamine 
in olfactory bulb explained why olfaction did not improve with levodopa therapy, 
which was the current treatment for PD (Schober, 2004). Under stress condition, 
dopaminergic neurons secreted high levels of chemokine-like signaling protein 
called Prokineticin-2 (PK2) as the compensatory protective response. In Dr. 
Kanthasamy’s study, a PK2 agonist IS20 was used to mimic the effect of PK2 in 
the primary culture. In addition, IS20 blocked MPTP-induced reductions in 
astrocytes (Neal, 2018).  
 
Methodology  
Mouse Model 
 The rodent model was utilized in order to trace the pathway of dopamine 
neurotransmitter from substantial nigra to olfactory bulb. The model consisted of 
12 mice, which was divided into two groups: littermate control and MitoPark. In 
the MitoPark group, the mice were further divided into two subgroups: one 
subgroup was treated with IS20, and the other subgroup was labeled vehicle (non-
ingested IS20). The littermate control group underwent the same division as the 
MitoPark group (Langley et al., 2017). The MitoPark model is a newer model 
recently popularized for PD study. It is a model knockout of tfam genes in 
dopaminergic neurons, which caused mitochondrial deficits (reduction of ATP) 
and death of dopaminergic neurons. In summary, the animal model recapitulates 
man PD-symptoms seen in human patients including olfactory deficits.  
Neuronal Tracers   
 There were three neuronal tracers injected in the model including 1,1’-
dioctadecyl-3, 3, 3,3’-tetramethylindocarbocyanine perchlorate – Dil (Bartheld, 
Cunningham, & Rubel, 1990), cholera toxin unit B – CTB (Conte, Kamishina, & 
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Reep, 2009), and Flouro-Gold (Schmued & Fallon, 1986). 1μl of Dil and 1μl of 
CTB were injected into the olfactory bulb site simultaneously from the same 
syringe at a rate of 0.4 μl/min for total of 5 minutes. Flouro-Gold was injected to 
the striatum site at a rate of 0.4 μl/min for total of 2.5 minutes. Later, the model 
brains were collected and stored at -20 degree Celsius with optimal cutting 
temperature (OCT) compound. 
Cryosectioning Technique 
 The technique was incorporated to separate brain cross-sectional images at 
coronal and sagittal planes. The frozen brain was mounted with OCT compound 
into the sample stubs. In the cryostat chamber, the stub was placed securely into 
the chuck with horizontal and vertical locks. The sectioning was performed at a 
thickness of 35 ηm. Each section was collected with angled brush and stored in 
sucrose and 1XPBS solution for cryoprotection (Beedle, 2016).  
Florescent Microscopy Technique 
 In order to visualize the dopaminergic pathway, the laboratory used 
fluorescent microscopy to trace the neurotransmitter. Generally, a fluorescence 
microscope contains an excitation filter, a dichroic beam splitter, and an emission 
filter. First, the excitation filter selects the interested wavelengths to excite a 
particular dye. Then, the emission filter serves as a kind of quality control since it 
only let the interested wavelengths pass through. After that, the dichroic mirror 
reflects the light in the excitation band and transmits the light in emission band for 
light illumination (Sanderson & Bootman, 2016). In the experiment, there were 
three stains emitted in the application. Dil stain emitted red color while CTB stain 
emitted green color at olfactory bulb injecting site. The Flouro-Gold stain emitted 
gold at striatum injecting site. 
Immunohistochemistry Technique 
 Immunohistochemistry (IHC) was utilized for additional section 
visualization. It combines anatomical, immunological, and biochemical techniques 
to image discrete components in tissues by using appropriately labeled antibodies 
to bind specifically to their target antigens in situ (Matos, Trufelli, De Matos & Da 
Silva Pinhal, 2010). Specifically, IHC is a 3-day long process. In first day, the 
interested sections are washed with phosphate buffer solution (PBS), and then 
incubated with methanol containing 3% H2O2. Next, blocking took place where 
the sections are incubated in blocking buffer for 60 minutes. To wrap up day 1, the 
sections are incubated in primary antibodies for 24 hours at 4°C. 
 In the second day, the process begins with washing the sections with PBS 
and incubating in second antibodies for 60 minutes at room temperature. Next, the 
sections are washed with PBS and incubated in ABC solution for 1 hour. After 
washing with PBS, the color development took place with the combination of 50μl 
of 30% H2O2 in 15 ml dH2O, 25 mg DAB in 50 ml PBS, and 250 diluted H2O2. 
The sections are incubated in DAB solution for 60 seconds and washed with PBS. 
Then, the sections are dipped in cresyl violet dye for 4-6 minutes. Washing in 
deionized water stops the reaction moving forward. Next, washing in 70% ethanol 
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for 3 minutes washes off cresyl violet deionized H2O. In day 3, the washing 
continues taking place with the following order: 50% Ethanol, 70% Ethanol, 95% 
Ethanol, 100% Ethanol, Xylene 1, and Xylene 2 (Matos, Trufelli, De Matos & Da 
Silva Pinhal, 2010).  
Results 
Table 1. Identification of MitoPark Mice Table  
 
 
 
 
 
 
 
 
 
Table 2. Identification of Littermate Control Mice Table  
 
 
 
 
 
 
 
 
  
Figure 1. FlouroGold Tracer in Striatum 
of 02K-MPV 
Figure 2. CTB Tracer is Olfactory Bulb 
of 02L-MPV 
Mouse ID Mouse Cage No Gender  Date of Birth 
02K 127240 M 04.01.18 
02L 127240 M 04.01.18 
02O 127237 M 04.09.18 
02V 127238 F 04.01.18 
03A 127239 M 04.04.18 
03B 127241 M 05.06.18 
Mouse ID Mouse Cage No Gender Date of Birth 
02M 127233 M 04.09.18 
02P 127233 M 04.09.18 
02H 127232 M 04.03.18 
02T 127235 F 04.01.18 
02X(DIE) 127236 F 04.01.18 
02Q 127234 F 03.23.18 
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Figure 3. FlouroGold Tracer in 
Substantia Nigra of 02L-MPV 
Figure 4. Dil Tracer in Olfactory Bulb 
 
  
Figure 5. CTB Tracer in Olfactory 
Bulb 
Figure 6. Dil and CTB Tracers in 
Olfactory Bulb 
Discussion 
 In order to validate the hypothesis, the MitoPark model was utilized with 
conditional TFAM knockout. Parkinson’s Disease tends to disrupt mitochondrial 
activity. One of the essential genes is tfam gene, which regulates the mitochondria 
DNA replication and transcription. Moreover, the gene also got involved in 
dopaminergic transporter (DAT) transcription. Therefore, inactivating tfam gene in 
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MitoPark model would result in dopamine deficits in these mice. Moreover, the 
role of dopamine in olfactory bulb is not well understood (Hollinger et al., 2015). 
6-OHDA and MPTP were neurotoxins used in the experiment to generate the loss 
of dopaminergic neurons. 
 In Table 1 and Table 2, each mouse was identified and recorded with its 
date of birth for both littermate control and MitoPark model. Unfortunately, 02X 
in littermate control was found dead before injection day. However, its brain was 
collected for further experiment. According to Figure 1, the FlouroGold tracer 
emitted blue fluorescent in the striatum of 02K (MitoPark-Vehicle), where it was 
initially injected. FlouroGold was a retrograde tracer starting from the terminal 
ends toward the cell bodies, which were located at Substantia Nigra par compacta. 
In Figure 3, there was not significant fluorescent of FlouroGold in Substantia 
Nigra due to the retrograde effect of the tracer. In Figure 2, the CTB tracer emitted 
green fluorescent in the olfactory bulb of 02L (MitoPark-Vehicle). However, in 
the experiment, there was not significant fluorescent of CTB in olfactory bulb. 
Figure 5 and Figure 6 gave a better visualization of CTB and Dil fluorescents. For 
future studies, we may collect more images having CTB and Dil tracers to validate 
the hypothesis.  
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